Toll-like receptor ligands energize peptide vaccines through multiple paths.
The potential of vaccines for cancer therapy or prevention has yet to be realized. Recently, we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR) ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer. By increasing the cross talk between the innate and adaptive immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy cancer cells.
Celis
Esteban
E
Immunology Program and Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA. ecelis@moffitt.org
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001943:Breast Neoplasms / Q000628:therapy; D019496:Cancer Vaccines / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D008024:Ligands; D008954:Models, Biological; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D015398:Signal Transduction / Q000187:drug effects; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000502:physiology; D051193:Toll-Like Receptors / Q000378:metabolism*; D022223:Vaccines, Subunit / Q000627:therapeutic use*